Based on current knowledge more than 95% of MSD patients harbor at least one SUMF1 missense allele and therefore may benefit from tazarotene/bexarotene treatment, which, according to our data, could act by stabilization of hypomorphic FGE variants (Schlotawa et al, 2020). Here, SUMF1 is linked to Multiple sulfatase deficiency.